1. In Vivo
  2. >>Business Strategy

US Biosimilars: Busting Blockbusters Or Managing Obsolescence?

 
• By John Hodgson

As a new generation of biosimilars challenge some of pharma’s biggest-selling products, this In Vivo analysis looks at how the originator blockbuster might fare in the face of competition. Experience in Europe, which predates that in the US by about a decade, provides a number of crucial pointers to outcomes and defensive strategies.

US Biosimilars

The stage is now set for an attritional war in biologics in the US. The US Congress may decide to pull back from the Affordable Care Act, but the regulatory pathway for biosimilars in the US is very likely to remain intact. In recent months, the FDA has approved or progressed biologics license applications from a number of biosimilar developers both in the US and outside for products that reference several of the world’s biggest selling biologics. These include biosimilars that challenge biologics with current (2016) global sales in excess of $50 billion, including Amgen Inc./Pfizer Inc.'s Enbrel (eterancept), Johnson & Johnson's Remicade (infliximab), Roche's Herceptin (trastuzumab) and at the top of the pile, Abbvie Inc.'s Humira(adalumimab). (See Exhibit 1.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo